Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.
OBJECTIVE
The purposes of this article are to review the current management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) based on the 2012 National Comprehensive Cancer Network guidelines and to describe the role of imaging in a multidisciplinary approach.


CONCLUSIONS
The management of GEP-NETs has become complex, requiring a multidisciplinary approach. The World Health Organization classification of GEP-NETs has been revised; the U.S. Food and Drug Administration has approved molecular targeted agents (sunitinib, everolimus) for the treatment of pancreatic NETs; and the National Comprehensive Cancer Network clinical practice guidelines have been updated.
1 Department of Radiology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115.
Kyung Won
KW
Kim
Katherine M
KM
Krajewski
Mizuki
M
Nishino
Jyothi P
JP
Jagannathan
Atul B
AB
Shinagare
Sree Harsha
SH
Tirumani
Nikhil H
NH
Ramaiya
D000368:Aged; D000369:Aged, 80 and over; D003952:Diagnostic Imaging / Q000379:methods* / Q000592:standards; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000592:standards / Q000639:trends; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome